RxDoctor Payments Data

Austin Mansfield

Psychiatric/Mental Health · Washington, UTNPI 1568191088

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 96.5% of the total across 184 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 24 manufacturers, the largest accounting for just 19.6% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2024 at $2,067 and has fallen 98.5% since, to $30 in 2025.

$3,276in general payments, 2019–2025

Across 184 payments — averaging $17.81 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Teva Pharmaceuticals USA, Inc.$641
  • Johnson & Johnson$374
  • AbbVie$283
  • Neurocrine Biosciences, Inc.$279
  • ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$274
  • Axsome Therapeutics, Inc.$265
  • plus $1K from 18 others

What the payments were for

  • Consulting fees$1154%
  • Food & beverage$3,16196%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$3,276 in reported general payments places this provider in the 85th percentile of 393 psychiatric/mental health providers in Utah.

See all psychiatric/mental health providers in Utah

Medicare billing

Part B allowed, 2024
$11,206
Medicare patients
39
Services billed
128

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
TrintellixVortioxetine Hydrobromide12$5,901
Methylphenidate ErMethylphenidate Hcl11$2,702
Aripiprazole28$1,770
Hydroxyzine Pamoate40$664
Fluoxetine Hcl23$403
Quetiapine Fumarate32$329
Sertraline Hcl43$256
Trazodone Hcl54$238
Escitalopram Oxalate21$205
Duloxetine Hcl11$199
Gabapentin12$187
Buspirone Hcl20$173
Zolpidem Tartrate15$145
Lorazepam11$124
Lamotrigine26$121

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Takeda Pharmaceuticals U.S.A., Inc.Trintellix$15$5,90112 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 393 psychiatric/mental health providers in Utah.

Other psychiatric/mental health in Washington

See the full list for Utah

Where these figures come from

Is this you, or does something look wrong? →